RecruitingPhase 2NCT05067348

Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis

A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial of the Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis

Sponsor

Tang-Du Hospital

Enrollment

64 participants

Start Date

Jul 21, 2022

Study Type

INTERVENTIONAL

Conditions

Myasthenia Gravis, Generalized

Summary

Randomized, double-blind, placebo-controlled, parallel-group study with optional open-label extension.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Tocilizumab Injectable Product for people with myasthenia gravis, generalized. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.